Trial Profile

An Open-Label, Single-Arm, Multicenter Pilot Study to Evaluate Safety, Tolerability, and Efficacy of ALN-PCSSC in Subjects With Homozygous Familial Hypercholesterolemia (HoFH)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Inclisiran (Primary)
Indications Hyperlipoproteinaemia type IIa
Focus Therapeutic Use
Acronyms ORION-2
Sponsors The Medicines Company

Most Recent Events

27 May 2019 According to The Medicines Company media release, data from the study were presented at the 87th European Atherosclerosis Society (EAS) Congress 2019.
27 May 2019 Results presented in The Medicines Company media release.
25 Apr 2019 According to the Medicines Company, data from this trial will be presented during a late-breaking abstract session at the 87th European Atherosclerosis Society Congress on May 27, 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com